概要
両末端にカルボン酸およびアミノ基を持つPEGは、非常に多くの官能基に対して反応性を持つため、PEG化において有用な試薬です。前述のような溶解性の向上、アグリゲーションの低下、免疫原性の抑制だけでなく、排除体積効果の増大による非特異的な吸着の回避を目的とした固体表面への修飾にもお使いいただけます。
頻繁に用いられる、末端にNHS(N-ヒドロキシコハク酸イミド)基を持つPEGは、アミノ基と非常に高い反応性を持つため非常に有用ですが、一方で目的によって実験条件を細かく設定することが求められます(液相 / 固相、有機溶媒 / 水系溶媒、生体分子(高分子)/ 低分子)。
a)
水系溶媒の場合、必ずアミンフリーのバッファを用いるようにしてください。NHS-PEGは乾燥したDMAC(ジメチルアセトアミド)、DMSO(ジメチルスホキシド)、DMF(ジメチルホルムアミド)中で保存することができます。調整を適正な条件で行い、湿気を避けることで-20
℃で数か月間の保管が可能です。反応溶媒にNHS-PEGを加え、30分から2時間で反応は終了します。NHSの半減期は温度、pH、構造に依存します(下表.1参照)。
b)
有機溶媒の場合、一般には反応を促進する塩基としてTEA(トリエチルアミン)、DIPEA(ジイソプロピルエチルアミン)、DBU(ジアザビシクロウンデセン)等の第3級アミンを用います。反応停止後の処理の簡便化のため、ジクロロメタンを溶媒として用いることをお薦めしています。修飾を行いたい化合物がジクロロメタンに難溶もしくは不溶である場合は、DMFなどを用います。最初は不溶のスラリー状の化合物もPEG化によって液体として得られます。
表1. アミノリシス*に対するPEG-NHSの反応性(25 ℃)
Structure of the Active Ester | Corresponding Acid | t1/2 [min] pH 8 | t1/2 [min] pH 7** | t1/2 [min] pH 6** | ||
---|---|---|---|---|---|---|
PEG-O-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-CO<sub>2</sub>-NHS | 酪酸 | 23.3 | 70 | 210 | ||
PEG-O-CO<sub>2</sub>-NHS | カルボン酸 | 20.4 | 61 | 183 | ||
PEG-O<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>-NHS | グルタル酸 | 17.6 | 53 | 159 | ||
PEG-O-CH<sub>2</sub>CH<sub>2</sub>-CO<sub>2</sub>-NHS | プロピオン酸 | 16.5 | 49 | 147 | ||
PEG-S-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>-NHS | メルカプトプロピオン酸 | 10.7 | 32 | 96 | ||
PEG-O<sub>2</sub>C-CH<sub>2</sub>CH<sub>2</sub>-CO<sub>2</sub>-NHS | コハク酸 | 9.8 | 29 | 87 | ||
PEG-NH-CO-CH<sub>2</sub>CH<sub>2</sub>-CO<sub>2</sub>-NHS | 4-オキソ-4-アミノ酪酸 | 3.2 | 9 | 27 | ||
PEG-O-CH<sub>2</sub>-CO<sub>2</sub>-NHS | 酢酸 | 0.75 | 2.25 | 6.75 |
* アミノリシスと加水分解は同様の反応機構で進行しますが、pH8付近ではアミノリシスが優先します。
** pH8の時点での値との比較
PEG-COOHを例えばNHSとEDCで活性化することで in situ 条件での使用も可能です。
ジクロロメタン(3Åのモレキュラーシーブ上で乾燥)を用いPEG-COOHの溶液を作成し、同じく乾燥条件下でEDC(1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド)およびNHSを加えます(NHS、EDCは1.1-1.2等量加えます。また、酸無水物の生成を避けるためNHSとEDCは同時に加えます)。オーバーナイトにて反応を行い、溶媒を乾燥させたのち使用します。
過剰のEDCおよび副生成物である尿素は少量のシリカゲルによっても除去することが可能です。縮合剤はDCC(ジシクロヘキシルカルボジイミド)、DIC(ジイソプロピルカルボジイミド)も使用可能です。NHSだけでなく、PfOH(ペンタフルオロフェノール)、MSNT(1-(メシチレン-2-スルホニル)-3-ニトロ-1,2,4-トリアゾール)、HOCt(エチル-1-ヒドロキシ1H-1,2,3-トリアゾール-4-カルボン酸)、HOPO(2-ヒドロキシピリジン-N-オキサイド)などもお使いいただけます。
参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier 2008; Ch. 18: 711-742; ISBN 978-0-12-370501-3
保護基ごとの製品一覧表
Aloc保護基を有するPEG
表2. Aloc保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
AAA1905.0001 | Aloc-O2Oc-OH*DCHA | C10H17NO6*C12H23N | 560088-74-6 | 247.11*181.32 | 1g | 8-(Allyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine |
AAA1905.0005 | Aloc-O2Oc-OH*DCHA | C10H17NO6*C12H23N | 560088-74-6 | 247.11*181.32 | 5g | 8-(Allyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine |
AAA1905.0025 | Aloc-O2Oc-OH*DCHA | C10H17NO6*C12H23N | 560088-74-6 | 247.11*181.32 | 25g | 8-(Allyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine |
Boc保護基を有するPEG
表3. Boc保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
BAA1466.0005 | Boc-O2Oc-OH*DCHA | C11H21NO6*C12H23N | 560088-79-1 | 263.29*181.32 | 5g | 8-(t-Butyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylammonium salt |
BAA1466.0025 | Boc-O2Oc-OH*DCHA | C11H21NO6*C12H23N | 560088-79-1 | 263.29*181.32 | 25g | 8-(t-Butyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylammonium salt |
BAA1485.0001 | Boc-O2Oc-O2Oc-OH | C17H32N2O9 | 1069067-08-8 | 408.45 | 1g | 17-(t-Butyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid |
BAA1485.0005 | Boc-O2Oc-O2Oc-OH | C17H32N2O9 | 1069067-08-8 | 408.45 | 5g | 17-(t-Butyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid |
BAA1485.0025 | Boc-O2Oc-O2Oc-OH | C17H32N2O9 | 1069067-08-8 | 408.45 | 25g | 17-(t-Butyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid |
BAA5240.0005 | Boc-O1Pen-OH*DCHA | C9H17NO5*C12H23N | 142929-49-5 net | 219.24*181.32 | 5g | 5-(t-Butyloxycarbonyl-amino)-3-oxapentanoic acid |
BAA5240.0025 | Boc-O1Pen-OH*DCHA | C9H17NO5*C12H23N | 142929-49-5 net | 219.24*181.32 | 25g | 5-(t-Butyloxycarbonyl-amino)-3-oxapentanoic acid |
BAA6070.0001 | Boc,Pbf-amidino-O1Pen-OH | C23H35N3O8S | 1263049-05-3 | 513.61 | 1g | 5-[N-t-Butyloxycarbonyl-N'-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)]amidino-3-oxapentanoic acid |
BAA6070.0005 | Boc,Pbf-amidino-O1Pen-OH | C23H35N3O8S | 1263049-05-3 | 513.61 | 5g | 5-[N-t-Butyloxycarbonyl-N'-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)]amidino-3-oxapentanoic acid |
BAA6070.0025 | Boc,Pbf-amidino-O1Pen-OH | C23H35N3O8S | 1263049-05-3 | 513.61 | 25g | 5-[N-t-Butyloxycarbonyl-N'-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)]amidino-3-oxapentanoic acid |
BAA6080.0001 | Boc,Pbf-amidino-O2Oc-OH | C25H39N3O9S | 1263049-06-4 | 557.66 | 1g | 8-[N-t-Butyloxycarbonyl-N'-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)]amidino-3,6-dioxaoctanoic acid |
BAA6080.0005 | Boc,Pbf-amidino-O2Oc-OH | C25H39N3O9S | 1263049-06-4 | 557.66 | 5g | 8-[N-t-Butyloxycarbonyl-N'-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)]amidino-3,6-dioxaoctanoic acid |
BAA6080.0025 | Boc,Pbf-amidino-O2Oc-OH | C25H39N3O9S | 1263049-06-4 | 557.66 | 25g | 8-[N-t-Butyloxycarbonyl-N'-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)]amidino-3,6-dioxaoctanoic acid |
PEG1920.0001 | Boc-NH-dPEG(4)-COOH | C16H31NO8 | 756525-91-4 | 365.42 | 1g | 15-t-Butyloxycarbonylamino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1920.0005 | Boc-NH-dPEG(4)-COOH | C16H31NO8 | 756525-91-4 | 365.42 | 5g | 15-t-Butyloxycarbonylamino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG4930.0001 | Boc-NH-PEG(3)-COOH | C14H27NO7 | - | 321.37 | 1g | 1-(t-Butyloxycarbonyl)amino-3,6,9-trioxadodecan-12-oic acid |
PEG4930.0005 | Boc-NH-PEG(3)-COOH | C14H27NO7 | - | 321.37 | 5g | 1-(t-Butyloxycarbonyl)amino-3,6,9-trioxadodecan-12-oic acid |
PEG4930.0025 | Boc-NH-PEG(3)-COOH | C14H27NO7 | - | 321.37 | 25g | 1-(t-Butyloxycarbonyl)amino-3,6,9-trioxadodecan-12-oic acid |
NHS-dPEG™(4)-NHNH-Boc
NHS-dPEG™ (4)-NHNH-BocはNHS基によって結合相手アミノ基と結合したのち、Boc基をTFAやHClを用いて酸性条件下で脱保護することでカルボン酸を官能基として有する化合物とを結合させることが可能です。
多くの生体分子はアミノ基もしくはカルボン酸を元々有しているか導入可能です。両末端に異なる官能基を持つPEGベースのクロスリンカーは、単純なメチレンポリマーと比較すると高い親水性を持つため、凝集を起こしにくいことなどが利点として挙げられます。
表4. NHS-dPEG™(4)-NHNH-Boc製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG1855.0001 | NHS-dPEG(4)-NHNH-Boc | C25H42N4O12 | 1203507-50-9 | 590.62 | 1g | 1-(N'-t-Butyloxycarbonyl)hydrazido-1,17-dioxo-4,7,10,13-tetraoxa-16-azahenicosan-21-oic acid succinimidyl ester |
PEG1855.0100 | NHS-dPEG(4)-NHNH-Boc | C25H42N4O12 | 1203507-50-9 | 590.62 | 100mg | 1-(N'-t-Butyloxycarbonyl)hydrazido-1,17-dioxo-4,7,10,13-tetraoxa-16-azahenicosan-21-oic acid succinimidyl ester |
Boc-NH-PEG(x)-COOH
表5. Boc-NH-PEG(x)-COOH
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG1070.0001 | Boc-NH-PEG(12)-COOH | C33H64N2O17 | - | 760.88 | 1g | alpha-t-Butyloxycarbonylamino-omega-[(aminocarboxymethoxy)acetic acid] dodecae(ethylene glycol) |
PEG1070.0005 | Boc-NH-PEG(12)-COOH | C33H64N2O17 | - | 760.88 | 5g | alpha-t-Butyloxycarbonylamino-omega-[(aminocarboxymethoxy)acetic acid] dodecae(ethylene glycol) |
PEG1071.0001 | Boc-NH-PEG(8)-COOH | C25H48N2O13 | - | 584.67 | 1g | alpha-t-Butyloxycarbonylamino-omega-diglycolic acid octa(ethylene glycol) |
PEG1071.0005 | Boc-NH-PEG(8)-COOH | C25H48N2O13 | - | 584.67 | 5g | alpha-t-Butyloxycarbonylamino-omega-diglycolic acid octa(ethylene glycol) |
PEG1072.0001 | Boc-NH-PEG-COOH | - | - | 10000 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1072.0500 | Boc-NH-PEG-COOH | - | - | 10000 | 500mg | alpha-t-Butyloxycarbonylamino-omega-carboxy poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1073.0001 | Boc-NH-PEG-COOH | - | - | 3000 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1073.0500 | Boc-NH-PEG-COOH | - | - | 3000 | 500mg | alpha-t-Butyloxycarbonylamino-omega-carboxy poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1074.0001 | Boc-NH-PEG-COOH | - | - | 5000 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1074.0500 | Boc-NH-PEG-COOH | - | - | 5000 | 500mg | alpha-t-Butyloxycarbonylamino-omega-carboxy poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1995.0001 | Boc-NH-PEG(27)-COOH | C64H127NO32 | - | 1422.71 | 1g | alpha-t-Butyloxycarbonylamino-27(ethylene glycol)-omega-propionic acid |
PEG1995.0005 | Boc-NH-PEG(27)-COOH | C64H127NO32 | - | 1422.71 | 5g | alpha-t-Butyloxycarbonylamino-27(ethylene glycol)-omega-propionic acid |
PEG2410.0001 | Boc-NH-PEG(8)-COOH | C24H47NO12 | 1334169-93-5 | 541.63 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy octa(ethylene glycol) |
PEG2410.0100 | Boc-NH-PEG(8)-COOH | C24H47NO12 | 1334169-93-5 | 541.63 | 100mg | alpha-t-Butyloxycarbonylamino-omega-carboxy octa(ethylene glycol) |
PEG2415.0001 | Boc-NH-PEG(12)-COOH | C32H63NO16 | 187848-68-6 | 717.84 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy dodeca(ethylene glycol) |
PEG2415.0100 | Boc-NH-PEG(12)-COOH | C32H63NO16 | 187848-68-6 | 717.84 | 100mg | alpha-t-Butyloxycarbonylamino-omega-carboxy dodeca(ethylene glycol) |
PEG4460.0000 | Boc-NH-dPEG™(16)-COOH | C40H79NO20 | 187848-68-6 | 894.05 | 0mg | alpha-t-Butyloxycarbonylamino-omega-carboxy hexadeca(ethylene glycol) |
PEG4470.0000 | Boc-NH-dPEG™(20)-COOH | C48H95NO24 | 187848-68-6 | 1070.26 | 0mg | alpha-t-Butyloxycarbonylamino-omega-carboxy 20(ethylene glycol) |
PEG4480.0100 | Boc-NH-dPEG™(24)-COOH | C56H111NO28 | 187848-68-6 | 1246.47 | 100mg | alpha-t-Butyloxycarbonylamino-omega-carboxy 24(ethylene glycol) |
PEG4480.1000 | Boc-NH-dPEG™(24)-COOH | C56H111NO28 | 187848-68-6 | 1246.47 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy 24(ethylene glycol) |
PEG4490.0100 | Boc-NH-dPEG™(36)-COOH | C80H159NO40 | 187848-68-6 | 1775.1 | 100mg | alpha-t-Butyloxycarbonylamino-omega-carboxy 36(ethylene glycol) |
PEG4490.1000 | Boc-NH-dPEG™(36)-COOH | C80H159NO40 | 187848-68-6 | 1775.1 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy 36(ethylene glycol) |
PEG4910.0001 | Boc-NH-PEG(6)-COOH | C20H39NO10 | 882847-13-4 | 453.52 | 1g | 1-(t-Butyloxycarbonyl)amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG4910.0005 | Boc-NH-PEG(6)-COOH | C20H39NO10 | 882847-13-4 | 453.52 | 5g | 1-(t-Butyloxycarbonyl)amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG4920.0001 | Boc-NH-PEG(5)-COOH | C18H35NO9 | - | 409.47 | 1g | 1-(t-Butyloxycarbonyl)amino-3,6,9,12,15-pentaoxaoctadecan-18-oic acid |
PEG4920.0005 | Boc-NH-PEG(5)-COOH | C18H35NO9 | - | 409.47 | 5g | 1-(t-Butyloxycarbonyl)amino-3,6,9,12,15-pentaoxaoctadecan-18-oic acid |
Boc-NH-PEG-NHS
表6. Boc-NH-PEG-NHS
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG1110.0001 | Boc-NH-PEG-NHS | - | - | 10000 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1110.0500 | Boc-NH-PEG-NHS | - | - | 10000 | 500mg | alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1111.0001 | Boc-NH-PEG-NHS | - | - | 3000 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1111.0500 | Boc-NH-PEG-NHS | - | - | 3000 | 500mg | alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1112.0001 | Boc-NH-PEG-NHS | - | - | 5000 | 1g | alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1112.0500 | Boc-NH-PEG-NHS | - | - | 5000 | 500mg | alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
Dde保護基を有するPEG製品
表7. Dde保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
DAA1016.0001 | Dde-O2Oc-OH | C16H25NO6 | - | 327.37 | 1g | 8-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-amino]-3,6-dioxaoctanoic acid, {2-[2-(Dde-amino)ethoxy]ethoxy}acetic acid |
DAA1016.0005 | Dde-O2Oc-OH | C16H25NO6 | - | 327.37 | 5g | 8-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-amino]-3,6-dioxaoctanoic acid, {2-[2-(Dde-amino)ethoxy]ethoxy}acetic acid |
DAA1016.0025 | Dde-O2Oc-OH | C16H25NO6 | - | 327.37 | 25g | 8-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-amino]-3,6-dioxaoctanoic acid, {2-[2-(Dde-amino)ethoxy]ethoxy}acetic acid |
アミン保護基としてのDde(1-(4,4-ジメチル-2,6-ジオキソシクロヘキシ-1-リデン)-エチル)
▶ DdeはBoc基やTrt基の脱保護条件である酸(TFA等)およびFmocの脱保護条件である塩基(ピペリジンやDBU)、さらにはAloc基の脱保護条件であるPd (0) のいずれでも脱保護されません。
▶ Ddeは通常2%のヒドラジン/DMF溶液によって脱保護されますが、Aloc保護基の存在下では定量的に進まないことが確認されています [1]。Fmoc基とは競合せず、Ddeは速やかに脱保護を受けることが報告されています。系中に他の保護基が存在する場合でも、NH2OH*HCl/イミダゾールのN-メチルピロリドン(NMP)/ジクロロメタン(DCM)溶液によってDdeは選択的に脱保護されます [2]。
▶ 副反応およびその抑制の手法は [1][3] に詳細の記載がございます。
▶ Ddeによって保護された化合物は固相合成にもお使いいただけます。
Dde保護基の選択的脱保護 (Mark Bradley et al.)
1.25 g (1.80 mmol) のNH2OH*HClおよび0.92 g (1.35 mmol) のイミダゾールを5 mLのNMPに加え、溶解するまで超音波処理します。この溶液は-20 ℃で2週間以上保存することが可能です。反応に使用する直前に、溶液5に対し、DMFまたはDCMを1の割合で薄めて使用します。
Dde保護基を用いた応用例
▶ Ddeによって保護されたアミノアルコール(とりわけチロシノール)は光延反応によるキラルビルディングブロック合成に最適であるとされています[4-6]。リシンの誘導体 [7] やペプチドミメティック [8-18]の固相合成に応用されています。また、オリゴヌクレオチドペプチドハイブリッド[19] 、糖ペプチド脂質 [20] 、シスチン不斉合成 [21]にも応用されています。
Dde保護基に関する参考文献
[1] Hydrazinolysis of Dde: Complete orthogonality with Aloc protecting groups; B. Rohwedder, Y. Mutti, P. Dumy and M. Mutter; Tetrahedron Lett 1998; 39: 1175-1178. doi:10.1016/S0040-4039(97)10810-3
[2] Full Orthogonality between Dde and Fmoc: The Direct Synthesis of PNA−Peptide Conjugates; J. J. Díaz-Mochón, L. Bialy and M. Bradley; Org Lett 2004; 6: 1127-1129. doi:10.1021/ol049905y
[3] Investigation on the stability of the Dde protecting group used in peptide synthesis: migration to an unprotected lysine; K. Augustyns, W. Kraas and G. Jung; J Pept Res 1998; 51: 127-33.
[4] Solid-Phase Synthesis of Tyrosine Peptide Aldehydes. Analogues of (S)-MAPI; P. Page, M. Bradley, I. Walters and S. Teague; J Org Chem 1999; 64: 794-799. doi:10.1021/jo981546v
[5] A latent aryl hydrazine ‘safety-catch’ linker compatible with N-alkylation; F. Berst, A. B. Holmes, M. Ladlow and P. J. Murray; Tetrahedron Lett 2000; 41: 6649-6653. doi:10.1016/S0040-4039(00)01108-4
[6] Solid-phase synthesis of Agel 416; a novel approach to modified polyamines; N. D. Hone and L. J. Payne; Tetrahedron Lett 2000; 41: 6149-6152. doi:http://dx.doi.org/10.1016/S0040-4039(00)00995-3
[7] Solid-phase synthesis of Nα-benzyl-Nα-cinnamyl lysine and glutamic acid derivatives; P. J. Connolly, K. N. Beers, S. K. Wetter and W. V. Murray; Tetrahedron Lett 2000; 41: 5187-5191. doi:10.1016/S0040-4039(00)00834-0
[8] Solid-phase total synthesis of polymyxin B1; S. K. Sharma, A. D. Wu,N. Chandramouli, C. Fotsch, G. Kardash and K. W. Bair; J Pept Res1999; 53: 501-506. doi:10.1034/j.1399-3011.1999.00045.x
[9] Solid-Phase Strategies for the Assembly of Template-Based Protein Mimetics1; S. Peluso, P. Dumy, C. Nkubana, Y. Yokokawa and M. Mutter; J Org Chem 1999; 64: 7114-7120. doi:10.1021/jo990669s
[10] On-line solid-phase synthesis of a peptide bi-derivatized with biotin and 4-azido salicylic acid; D. Lelièvre, D. Daguet and A. Brack; Tetrahedron Lett 1995; 36: 9317-9320. doi:10.1016⁄0040- 4039(95)02029-O
[11] Synthesis of a branched cyclic peptide using a strategy employing Fmoc chemistry and two additional orthogonal protecting groups; G. B. Bloomberg, D. Askin, A. R. Gargaro and M. J. A. Tanner; Tetrahedron Lett 1993; 34: 4709-4712. doi:10.1016/S0040-4039(00)60663-9
[12] A novel lysine-protecting procedure for continuous flow solid phase synthesis of branched peptides; B. W. Bycroft, W. C. Chan, S. R. Chhabra and N. D. Hone; J Cem Soc, Chem Comm 1993: 778-779. doi:10.1039/c39930000778
[13] Synthesis of a diepitope multiple antigen peptide containing sequences from two malaria antigens using Fmoc chemistry; N. Ahlborg; J Immun Meth 1995; 179: 269-275. doi:10.1016⁄0022- 1759(94)00328-T
[14] Cyclic peptide template combinatorial libraries: synthesis and identification of chymotrypsin inhibitors; J. Eichler, A. W. Lucka andR. A. Houghten; Pept Res 1994; 7: 300-7.
[15] Solid-phase synthesis and stability of triple-helical peptides incorporating native collagen sequences; C. G. Fields, C. M. Lovdahl, A. J. Miles, V. L. Hagen and G. B. Fields; Biopolymers 1993; 33: 1695-707.
[16] Solid-phase synthesis and application of double-fluorescent-labeledlipopeptides, containing a CTL-epitope from the measles fusion protein; P. Hoogerhout, K. J. Stittelaar, H. F. Brugghe, J. A. M. Timmermans, G. J. Ten Hove, W. Jiskoot, J. H. G. Hoekman and P. J. M. Roholl; J Pept Res 1999; 54: 436-443. doi:10.1034/j.1399-3011.1999.00128.x
[17] Infrared and Raman Spectra of a Single Resin Bead for Analysis of Solid-Phase Reactions and Use in Encoding Combinatorial Libraries; S. S. Rahman, D. J. Busby and D. C. Lee; J Org Chem 1998; 63: 6196- 6199. doi:10.1021/jo980258w
[18] Parallel solid-phase synthesis of vitronectin receptor (αvβ3) inhibitors; A. Gopalsamy, H. Yang, J. W. Ellingboe, K. L. Kees, J. Yoon and R. Murrills; Bioorg Med Chem Lett 2000; 10: 1715-1718. doi:10.1016/ S0960-894X(00)00319-X
[19] On-line solid phase synthesis of oligonucleotide-peptide hybrids using silica supports; J.-C. Truffert, O. Lorthioir, U. Asseline, N. T. Thuong and A. Brack; Tetrahedron Lett 1994; 35: 2353-2356. doi:10.1016⁄0040-4039(94)85218-9
[20] Synthesis and Supramolecular Characterization of a Novel Class of Glycopyranosyl-Containing Amphiphiles; F. Reichel, A. M. Roelofsen, H. P. M. Geurts, S. J. van der Gaast, M. C. Feiters and G. J. Boons; J Org Chem 2000; 65: 3357-3366. doi:10.1021/jo991685s
[21] Synthesis of asymmetric systines; S. Zuberi, A. Glen, R. C. Hider and S. S. Bansal; Tetrahedron Lett 1998; 39: 7567-7570. doi:10.1016/S0040-4039(98)01614-1
[22] Dde — A selective primary amine protecting group: A facile solid phase synthetic approach to polyamine conjugates; I. A. Nash, B. W. BycroG and W. C. Chan; Tetrahedron Lett 1996; 37: 2625-2628. doi:10.1016⁄0040-4039(96)00344-9
[23] Solid-Phase Synthesis of Bleomycin Group Antibiotics. Elaboration of Deglycobleomycin A5; C. J. Leitheiser, M. J. Rishel, X. Wu and S. M. Hecht; Org Lett 2000; 2: 3397-3399. doi:10.1021/ol0002469
[24] Solid phase applications of Dde and the analogue Nde: Synthesis of trypanothione disulphide; B. Kellam, B. W. BycroG and S. R. Chhabra; Tetrahedron Lett 1997; 38: 4849-4852. doi:10.1016/S0040-4039(97)01010-1
[25] N-Fmoc-aminooxy-2-chlorotrityl polystyrene resin: A facile solid- phase methodology for the synthesis of hydroxamic acids; S. L. Mellor, C. McGuire and W. C. Chan; Tetrahedron Lett 1997; 38: 3311- 3314. doi:10.1016/S0040-4039(97)00594-7
[26] Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728; N. Willand, J. Joossens, J.-C. Gesquière, A. L. Tartar, D. M. Evans and M. B. Roe; Tetrahedron 2002; 58: 5741-5746. doi:10.1016/S0040-4020(02)00536-7
Dnp保護基を有するPEG製品
抗DNP抗体の産生のためにKLH等のキャリアタンパクへの結合にDNP-PEGを用いることが可能です。
表8. Dnp保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG2145.0001 | Dnp-NH-PEG(4)-COOH | C17H25N3O10 | 858126-76-8 | 431.39 | 1g | 1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid |
PEG2145.0100 | Dnp-NH-PEG(4)-COOH | C17H25N3O10 | 858126-76-8 | 431.39 | 100mg | 1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid |
PEG2150.0001 | Dnp-NH-PEG(4)-NHS | C21H28N4O12 | 858126-78-0 | 528.47 | 1g | 1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid succinimidyl ester |
PEG2150.0100 | Dnp-NH-PEG(4)-NHS | C21H28N4O12 | 858126-78-0 | 528.47 | 100mg | 1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid succinimidyl ester |
PEG2285.0001 | Dnp-NH-PEG(12)-COOH | C33H57N3O18 | 1334178-00-5 | 783.81 | 1g | alpha-(2,4-Dinitrophenyl)amino-omega-carboxy dodeca(ethylene glycol) |
PEG2285.0100 | Dnp-NH-PEG(12)-COOH | C33H57N3O18 | 1334178-00-5 | 783.81 | 100mg | alpha-(2,4-Dinitrophenyl)amino-omega-carboxy dodeca(ethylene glycol) |
PEG2290.0001 | Dnp-NH-PEG(12)-NHS | C34H60N4O20 | 1334178-01-6 | 880.89 | 1g | alpha-(2,4-Dinitrophenyl)amino-omega-succinimidyl ester dodeca(ethylene glycol) |
PEG2290.0100 | Dnp-NH-PEG(12)-NHS | C34H60N4O20 | 1334178-01-6 | 880.89 | 100mg | alpha-(2,4-Dinitrophenyl)amino-omega-succinimidyl ester dodeca(ethylene glycol) |
Dnp保護基に関する参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier2008; Ch. 19; ISBN 978-0-12-370501-3
Fmoc保護基を有するPEG製品
表9. Fmoc保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
FAA1435.0001 | Fmoc-O2Oc-OH | C21H23NO6 | 166108-71-0 | 385.42 | 1g | 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid |
FAA1435.0005 | Fmoc-O2Oc-OH | C21H23NO6 | 166108-71-0 | 385.42 | 5g | 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid |
FAA1435.0025 | Fmoc-O2Oc-OH | C21H23NO6 | 166108-71-0 | 385.42 | 25g | 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid |
FAA1565.0001 | Fmoc-O1Pen-OH | C19H19NO5 | 260367-12-2 | 341.37 | 1g | 5-(9-Fluorenylmethyloxycarbonyl-amino)-3-oxapentanoic acid |
FAA1565.0005 | Fmoc-O1Pen-OH | C19H19NO5 | 260367-12-2 | 341.37 | 5g | 5-(9-Fluorenylmethyloxycarbonyl-amino)-3-oxapentanoic acid |
FAA1565.0025 | Fmoc-O1Pen-OH | C19H19NO5 | 260367-12-2 | 341.37 | 25g | 5-(9-Fluorenylmethyloxycarbonyl-amino)-3-oxapentanoic acid |
FAA1568.0001 | Fmoc-TTDS-OH | C29H38N2O8 | 172089-14-4 | 542.63 | 1g | [N1-(9-Fluorenylmethoxycarbonyl)-1,13-diamino-4,7,10-trioxatridecan-succinamic acid |
FAA1568.0005 | Fmoc-TTDS-OH | C29H38N2O8 | 172089-14-4 | 542.63 | 5g | [N1-(9-Fluorenylmethoxycarbonyl)-1,13-diamino-4,7,10-trioxatridecan-succinamic acid |
FAA1568.0025 | Fmoc-TTDS-OH | C29H38N2O8 | 172089-14-4 | 542.63 | 25g | [N1-(9-Fluorenylmethoxycarbonyl)-1,13-diamino-4,7,10-trioxatridecan-succinamic acid |
FAA1787.0001 | Fmoc-O2Oc-O2Oc-OH | C27H34N2O9 | 560088-89-3 | 530.58 | 1g | 17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid |
FAA1787.0005 | Fmoc-O2Oc-O2Oc-OH | C27H34N2O9 | 560088-89-3 | 530.58 | 5g | 17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid |
FAA1787.0025 | Fmoc-O2Oc-O2Oc-OH | C27H34N2O9 | 560088-89-3 | 530.58 | 25g | 17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid |
FAA6020.0001 | Fmoc-O2Oc-OPfp | C27H22F5NO6 | 1263044-39-8 | 551.5 | 1g | 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid pentafluorophenyl ester |
FAA6020.0005 | Fmoc-O2Oc-OPfp | C27H22F5NO6 | 1263044-39-8 | 551.5 | 5g | 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid pentafluorophenyl ester |
FAA6020.0025 | Fmoc-O2Oc-OPfp | C27H22F5NO6 | 1263044-39-8 | 551.5 | 25g | 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid pentafluorophenyl ester |
FAA6790.0001 | Fmoc-O2Oc-O2Oc-OPfp | C33H33F5N2O9 | - | 696.61 | 1g | 17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid pentafluorophenyl ester |
FAA6790.0005 | Fmoc-O2Oc-O2Oc-OPfp | C33H33F5N2O9 | - | 696.61 | 5g | 17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid pentafluorophenyl ester |
PEG1810.0001 | Fmoc-AEEP | C22H25NO6 | 872679-70-4 | 399.44 | 1g | 3-(2-(2-(9-Fluorenylmethyloxycarbonyl)aminoethoxy)ethoxy)propanoic acid |
PEG1810.0005 | Fmoc-AEEP | C22H25NO6 | 872679-70-4 | 399.44 | 5g | 3-(2-(2-(9-Fluorenylmethyloxycarbonyl)aminoethoxy)ethoxy)propanoic acid |
PEG1810.0025 | Fmoc-AEEP | C22H25NO6 | 872679-70-4 | 399.44 | 25g | 3-(2-(2-(9-Fluorenylmethyloxycarbonyl)aminoethoxy)ethoxy)propanoic acid |
PEG4970.0001 | Fmoc-Ebes | C25H30N2O7 | 613245-91-3 | 470.51 | 1g | N-[8-(9-Fluorenylmethyloxycarbonyl)amino-3,6-dioxaoctyl]succinamic acid |
PEG4970.0005 | Fmoc-Ebes | C25H30N2O7 | 613245-91-3 | 470.51 | 5g | N-[8-(9-Fluorenylmethyloxycarbonyl)amino-3,6-dioxaoctyl]succinamic acid |
PEG4970.0025 | Fmoc-Ebes | C25H30N2O7 | 613245-91-3 | 470.51 | 25g | N-[8-(9-Fluorenylmethyloxycarbonyl)amino-3,6-dioxaoctyl]succinamic acid |
PEG5180.0001 | Fmoc-DOOA-DIG-OH | C25H30N2O8 | 669073-64-7 | 486.51 | 1g | 2-(2-(2-(2-((9-Fluorenylmethyloxycarbonyl)amino)ethoxy)ethoxy)ethylamino)-diglycolic acid |
PEG5180.0005 | Fmoc-DOOA-DIG-OH | C25H30N2O8 | 669073-64-7 | 486.51 | 5g | 2-(2-(2-(2-((9-Fluorenylmethyloxycarbonyl)amino)ethoxy)ethoxy)ethylamino)-diglycolic acid |
PEG5180.0025 | Fmoc-DOOA-DIG-OH | C25H30N2O8 | 669073-64-7 | 486.51 | 25g | 2-(2-(2-(2-((9-Fluorenylmethyloxycarbonyl)amino)ethoxy)ethoxy)ethylamino)-diglycolic acid |
Fmoc-NH-PEG製品
表10. Fmoc-NH-PEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG1080.0001 | Fmoc-NH-PEG(12)-COOH | C42H65NO16 | 756526-01-9 | 839.98 | 1g | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid |
PEG1080.0100 | Fmoc-NH-PEG(12)-COOH | C42H65NO16 | 756526-01-9 | 839.98 | 100mg | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid |
PEG1107.0001 | Fmoc-NH-PEG-COOH | - | - | 10000 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1107.0500 | Fmoc-NH-PEG-COOH | - | - | 10000 | 500mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1108.0001 | Fmoc-NH-PEG-COOH | - | - | 3000 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1108.0500 | Fmoc-NH-PEG-COOH | - | - | 3000 | 500mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1109.0001 | Fmoc-NH-PEG-COOH | - | - | 5000 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1109.0500 | Fmoc-NH-PEG-COOH | - | - | 5000 | 500mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1116.0001 | Fmoc-NH-PEG-NHS | - | - | 10000 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1116.0500 | Fmoc-NH-PEG-NHS | - | - | 10000 | 500mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
PEG1117.0001 | Fmoc-NH-PEG-NHS | - | - | 3000 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1117.0500 | Fmoc-NH-PEG-NHS | - | - | 3000 | 500mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
PEG1118.0001 | Fmoc-NH-PEG-NHS | - | - | 5000 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1118.0500 | Fmoc-NH-PEG-NHS | - | - | 5000 | 500mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
PEG1210.0001 | Fmoc-NH-PEG(27)-COOH | C74H129NO32 | - | 1544.8 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-27(ethylene glycol)-omega-propionic acid |
PEG1210.0005 | Fmoc-NH-PEG(27)-COOH | C74H129NO32 | - | 1544.8 | 5g | alpha-(9-Fluorenylmethyloxycarbonyl)amino-27(ethylene glycol)-omega-propionic acid |
PEG1815.0001 | Fmoc-NH-dPEG(24)-COOH | C66H113NO28 | 756526-01-9 | 1368.63 | 1g | alpha-Fmoc-amino-24(ethylene glycol)-omega-carboxylic acid |
PEG1815.0100 | Fmoc-NH-dPEG(24)-COOH | C66H113NO28 | 756526-01-9 | 1368.63 | 100mg | alpha-Fmoc-amino-24(ethylene glycol)-omega-carboxylic acid |
PEG1820.0001 | Fmoc-NH-PEG(4)-COOH | C26H33NO8 | 557756-85-1 | 487.54 | 1g | 15-(9-Fluorenyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1820.0005 | Fmoc-NH-PEG(4)-COOH | C26H33NO8 | 557756-85-1 | 487.54 | 5g | 15-(9-Fluorenyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1825.0001 | Fmoc-NH-PEG(6)-COOH | C30H41NO10 | 882847-34-9 | 575.65 | 1g | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1825.0005 | Fmoc-NH-PEG(6)-COOH | C30H41NO10 | 882847-34-9 | 575.65 | 5g | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1830.0001 | Fmoc-NH-dPEG(8)-COOH | C34H49NO12 | 756526-02-0 | 663.75 | 1g | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid |
PEG1830.0005 | Fmoc-NH-dPEG(8)-COOH | C34H49NO12 | 756526-02-0 | 663.75 | 5g | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid |
PEG1830.0100 | Fmoc-NH-dPEG(8)-COOH | C34H49NO12 | 756526-02-0 | 663.75 | 100mg | 1-(9-Fluorenylmethyloxycarbonyl)amino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid |
PEG3180.0000 | Fmoc-NH-PEG(16)-COOH | C50H81NO20 | 756526-01-9 | 1016.17 | 0mg | alpha-(9-Fluorenylmethyloxycarbonyl)amino-omega-carboxy hexadeca(ethylene glycol) |
PEG4370.1000 | Fmoc-NH-PEG(3)-COOH | C24H29NO7 | 867062-95-1 | 443.49 | 1g | 12-(9-Fluorenyloxycarbonylamino)-4,7,10-trioxa-dodecanoic acid |
PEG4370.5000 | Fmoc-NH-PEG(3)-COOH | C24H29NO7 | 867062-95-1 | 443.49 | 5g | 12-(9-Fluorenyloxycarbonylamino)-4,7,10-trioxa-dodecanoic acid |
PEG4380.1000 | Fmoc-NH-PEG(5)-COOH | C28H37NO9 | 882847-32-7 | 531.59 | 1g | 18-(9-Fluorenyloxycarbonylamino)-4,7,10, 13-tetraoxa-octadecanoic acid |
PEG4380.5000 | Fmoc-NH-PEG(5)-COOH | C28H37NO9 | 882847-32-7 | 531.59 | 5g | 18-(9-Fluorenyloxycarbonylamino)-4,7,10, 13-tetraoxa-octadecanoic acid |
PEG4380.9025 | Fmoc-NH-PEG(5)-COOH | C28H37NO9 | 882847-32-7 | 531.59 | 25g | 18-(9-Fluorenyloxycarbonylamino)-4,7,10, 13-tetraoxa-octadecanoic acid |
PEG4400.0100 | Fmoc-NH-dPEG™(36)-COOH | C90H161NO40 | 756526-01-9 | 1897.22 | 100mg | alpha-Fmoc-amino-36(ethylene glycol)-omega-carboxylic acid |
PEG4400.1000 | Fmoc-NH-dPEG™(36)-COOH | C90H161NO40 | 756526-01-9 | 1897.22 | 1g | alpha-Fmoc-amino-36(ethylene glycol)-omega-carboxylic acid |
PEG4410.0100 | Fmoc-NH-dPEG™(4)-NHS | C30H36N2O10 | 1314378-14-7 | 584.24 | 100mg | 15-(9-Fluorenyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoic acid succinimidyl ester |
PEG4410.1000 | Fmoc-NH-dPEG™(4)-NHS | C30H36N2O10 | 1314378-14-7 | 584.24 | 1g | 15-(9-Fluorenyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoic acid succinimidyl ester |
PEG4420.0100 | Fmoc-NH-dPEG™(8)-NHS | C38H52N2O14 | 1334170-03-4 | 760.82 | 100mg | alpha-(Fmoc-amino)-omega-(succinimidyl propionate) octa(ethylene glycol) |
PEG4420.1000 | Fmoc-NH-dPEG™(8)-NHS | C38H52N2O14 | 1334170-03-4 | 760.82 | 1g | alpha-(Fmoc-amino)-omega-(succinimidyl propionate) octa(ethylene glycol) |
PEG4430.0100 | Fmoc-NH-dPEG™(12)-NHS | C46H68N2O18 | 488085-18-3 | 937.03 | 100mg | alpha-(Fmoc-amino)-omega-(succinimidyl propionate) dodeca(ethylene glycol) |
PEG4430.1000 | Fmoc-NH-dPEG™(12)-NHS | C46H68N2O18 | 488085-18-3 | 937.03 | 1g | alpha-(Fmoc-amino)-omega-(succinimidyl propionate) dodeca(ethylene glycol) |
PEG4630.0100 | Phth-NO-dPEG™(12)-NHS | C39H60N2O19 | - | 860.9 | 100mg | alpha-Pthaloylaminoxy-omega-(succinimidyl propionate)-dodeca(ethylene glycol) |
PEG4630.1000 | Phth-NO-dPEG™(12)-NHS | C39H60N2O19 | - | 860.9 | 1g | alpha-Pthaloylaminoxy-omega-(succinimidyl propionate)-dodeca(ethylene glycol) |
PEG4670.0100 | Fmoc-NH-O-dPEG™(12)-COOH | C42H65NO17 | - | 855.96 | 100mg | alpha-(9-Fluorenylmethyloxycarbonyl-aminoxy)-omega-(propionic acid)-dodeca(ethylene glycol) |
PEG4670.1000 | Fmoc-NH-O-dPEG™(12)-COOH | C42H65NO17 | - | 855.96 | 1g | alpha-(9-Fluorenylmethyloxycarbonyl-aminoxy)-omega-(propionic acid)-dodeca(ethylene glycol) |
MttおよびMmt保護基を有するPEG製品
Mtt(メチルトリチル基)およびMmt(メトキシトリチル基)は、Fmocと直交な関係にあり、非常に穏やかな条件での脱保護が可能です。例えば、低濃度のTFAおよびHFIP(ヘキサフルオロイソプロパノール)、20%のTFE(トリフルオロエタノール)のジクロロメタン溶液などです。
表11. MttおよびMmt保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG2265.0001 | Mmt-NH-PEG(8)-COOH | C39H55NO11 | 1334177-98-8 | 713.85 | 1g | alpha-p-Methoxytritylamino-omega-carboxy octa(ethylene glycol) |
PEG2265.0100 | Mmt-NH-PEG(8)-COOH | C39H55NO11 | 1334177-98-8 | 713.85 | 100mg | alpha-p-Methoxytritylamino-omega-carboxy octa(ethylene glycol) |
PEG2270.0001 | Mmt-NH-PEG(12)-COOH | C47H71NO15 | 1334177-99-9 | 890.06 | 1g | alpha-p-Methoxytritylamino-omega-carboxy dodeca(ethylene glycol) |
PEG2270.0100 | Mmt-NH-PEG(12)-COOH | C47H71NO15 | 1334177-99-9 | 890.06 | 100mg | alpha-p-Methoxytritylamino-omega-carboxy dodeca(ethylene glycol) |
PEG2275.0000 | Mmt-NH-PEG(16)-COOH | C55H87NO19 | 1334177-99-9 | 1066.27 | 0g | alpha-p-Methoxytritylamino-omega-carboxy hexadeca(ethylene glycol) |
PEG2280.0001 | Mmt-NH-PEG(24)-COOH | C71H119NO27 | 1334177-99-9 | 1418.7 | 1g | alpha-p-Methoxytritylamino-omega-carboxy 24(ethylene glycol) |
PEG2280.0100 | Mmt-NH-PEG(24)-COOH | C71H119NO27 | 1334177-99-9 | 1418.7 | 100mg | alpha-p-Methoxytritylamino-omega-carboxy 24(ethylene glycol) |
PEG4500.0100 | Mmt-NH-dPEG™(4)-TFP | C37H39F4NO7 | 1314378-09-0 | 685.7 | 100mg | 15-(p-Methoxytritylamino)-4,7,10,13-tetraoxa-pentadecanoic acid 2,3,5,6-tetrafluorphenyl ester |
PEG4500.1000 | Mmt-NH-dPEG™(4)-TFP | C37H39F4NO7 | 1314378-09-0 | 685.7 | 1g | 15-(p-Methoxytritylamino)-4,7,10,13-tetraoxa-pentadecanoic acid 2,3,5,6-tetrafluorphenyl ester |
PEG4510.0100 | Mmt-NH-dPEG™(8)-TFP | C45H55F4NO11 | 1334169-91-3 | 861.91 | 100mg | alpha-p-Methoxytritylamino-omega-(2,3,5,6-tetrafluorphenyl propionate) octa(ethylene glycol) |
PEG4510.1000 | Mmt-NH-dPEG™(8)-TFP | C45H55F4NO11 | 1334169-91-3 | 861.91 | 1g | alpha-p-Methoxytritylamino-omega-(2,3,5,6-tetrafluorphenyl propionate) octa(ethylene glycol) |
PEG4520.0100 | Mmt-NH-dPEG™(12)-TFP | C53H71F4NO15 | 1334169-92-4 | 1038.12 | 100mg | alpha-p-Methoxytritylamino-omega-(2,3,5,6-tetrafluorphenyl propionate) dodeca(ethylene glycol) |
PEG4520.1000 | Mmt-NH-dPEG™(12)-TFP | C53H71F4NO15 | 1334169-92-4 | 1038.12 | 1g | alpha-p-Methoxytritylamino-omega-(2,3,5,6-tetrafluorphenyl propionate) dodeca(ethylene glycol) |
PEG4650.0001 | Mtt-O2Oc-OH*DEA | C26H29NO4*C4H11N | - | 419.51*73.14 | 1g | N-(4-Methyltrity)-8-amino-3,6-dioxaoctanoic acid diethylamine |
PEG4650.0005 | Mtt-O2Oc-OH*DEA | C26H29NO4*C4H11N | - | 419.51*73.14 | 5g | N-(4-Methyltrity)-8-amino-3,6-dioxaoctanoic acid diethylamine |
PEG4650.0025 | Mtt-O2Oc-OH*DEA | C26H29NO4*C4H11N | - | 419.51*73.14 | 25g | N-(4-Methyltrity)-8-amino-3,6-dioxaoctanoic acid diethylamine |
MttおよびMmt保護基に関する参考文献
▷ Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles;G. M. Dubowchik and S. Radia; Tetrahedron Lett 1997; 38: 5257-5260. doi:10.1016/S0040-4039(97)01158-1
▷ Evaluation of monomethoxytrityl and dimethoxytrityl as orthogonal amino protecting groups in Fmoc solid phase peptide synthesis; S. Matysiak, T. Böldicke, W. Tegge and R. Frank; Tetrahedron Lett 1998; 39: 1733-1734. doi:10.1016/S0040-4039(98)00055-0
▷ The synthesis of polyamide nucleic acids using a novel monomethoxytrityl protecting-group strategy; D. W. Will, G. Breipohl, D. Langner, J. Knolle and E. Uhlmann; Tetrahedron 1995; 51: 12069- 12082. doi:10.1016⁄0040-4020(95)00766-2
▷ Preparation of the very acid-sensitive Fmoc-Lys(Mtt)-OH. Application in the synthesis of side-chain to side-chain cyclic peptides and oligolysine cores suitable for the solid-phase assembly of MAPs and TASPs; A. Aletras, K. Barlos, D. Gatos, S. Koutsogianni and P. Mamos; Int J Pept Protein Res 1995; 45: 488-96.
無保護N末端を有するPEG製品
▶ PEG化を行うことで、水溶性の向上、凝集性の抑制、非特異的吸着の防止を計ることが可能です。導入は化学的な手法によって容易に行うことができます。また、これらの化合物は双性イオンであり、水溶性が高く、中程度の極性を持つ溶媒にも溶解します。
▶ 一部の化合物に付与されているt-Bu基は25%TFA/DCM溶液によって脱保護可能です(0 ℃、5時間)。また、その疎水性から精製を簡便にし、双性イオンを中性化することで、アミノ基の反応性を保つことができます。
これらの化合物はビーズのみでなくナノ粒子のコーティング等にも適用可能です。カルボン酸末端の比率は、同等もしくは少し短い末端アミノ基を持つメトキシPEGを用いることで調節可能です。
参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier 2008; Ch. 14: 582-626; ISBN 978-0-12-370501-3.
活性化エステルに対する手順例
乾燥溶媒に活性化エステルを溶解し、塩基(TEAなど)を加えます。そこへ末端アミノ基を持つPEG溶液を加えます。試薬は活性エステルに対し最低10%以上多く加えます。この反応は室温でも十分進行します。
末端カルボニル基に対する手順例
縮合剤(EDCなど)とともにNHSなどの活性末端となる試薬を混合し、カルボン酸を活性化します。そののち、塩基(TEAなど)および末端アミノ基を持つPEGを加え、反応を進行させます。EDC以外のカルボジイミド系の縮合剤を用いることも可能ですがこの場合系中から除去しにくい尿素が副生成物として得られるため、精製の簡便化を図る場合はDCC、DICよりもEDCを選択するとよいでしょう。反応は-10℃から0℃で進行します。
無保護N-末端を有するPEG製品
表12. 無保護N-末端を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG1095.0001 | H2N-PEG-COOH*HCl | - | - | 10000 | 1g | alpha-Amino-omega-carboxy poly(ethylene glycol) hydrochloride (PEG-MW 10.000 Dalton) |
PEG1095.0500 | H2N-PEG-COOH*HCl | - | - | 10000 | 500mg | alpha-Amino-omega-carboxy poly(ethylene glycol) hydrochloride (PEG-MW 10.000 Dalton) |
PEG1096.0001 | H2N-PEG-COOH*HCl | - | - | 3000 | 1g | alpha-Amino-omega-carboxy poly(ethylene glycol) hydrochloride (PEG-MW 3.000 Dalton) |
PEG1096.0500 | H2N-PEG-COOH*HCl | - | - | 3000 | 500mg | alpha-Amino-omega-carboxy poly(ethylene glycol) hydrochloride (PEG-MW 3.000 Dalton) |
PEG1097.0001 | H2N-PEG-COOH*HCl | - | - | 5000 | 1g | alpha-Amino-omega-carboxy poly(ethylene glycol) hydrochloride (PEG-MW 5.000 Dalton) |
PEG1097.0500 | H2N-PEG-COOH*HCl | - | - | 5000 | 500mg | alpha-Amino-omega-carboxy poly(ethylene glycol) hydrochloride (PEG-MW 5.000 Dalton) |
PEG1221.0001 | H-O2Oc-O2Oc-OH | C12H24N2O7 | 1143516-05-5 | 308.33 | 1g | 17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oic acid |
PEG1221.0005 | H-O2Oc-O2Oc-OH | C12H24N2O7 | 1143516-05-5 | 308.33 | 5g | 17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oic acid |
PEG1300.0001 | H2N-dPEG(6)-COOH | C15H31NO8 | 905954-28-1 | 353.41 | 1g | 1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1300.0005 | H2N-dPEG(6)-COOH | C15H31NO8 | 905954-28-1 | 353.41 | 5g | 1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1300.0250 | H2N-dPEG(6)-COOH | C15H31NO8 | 905954-28-1 | 353.41 | 250mg | 1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1305.0001 | H2N-dPEG(6)-CO-OtBu | C19H39NO8 | 1286281-32-0 | 409.51 | 1g | 1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid t-butyl ester |
PEG1305.0100 | H2N-dPEG(6)-CO-OtBu | C19H39NO8 | 1286281-32-0 | 409.51 | 100mg | 1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid t-butyl ester |
PEG1345.0001 | H2N-dPEG(12)-COOH | C27H55NO14 | 756526-07-4 | 617.72 | 1g | 1-Amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid |
PEG1345.0100 | H2N-dPEG(12)-COOH | C27H55NO14 | 756526-07-4 | 617.72 | 100mg | 1-Amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid |
PEG1350.0001 | H2N-dPEG(12)-CO-OtBu | C31H63NO14 | 872340-65-3 | 673.83 | 1g | 1-Amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid t-butyl ester |
PEG1350.0100 | H2N-dPEG(12)-CO-OtBu | C31H63NO14 | 872340-65-3 | 673.83 | 100mg | 1-Amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid t-butyl ester |
PEG1355.0001 | H2N-dPEG(24)-COOH | C51H103NO26 | 756526-07-4 | 1146.38 | 1g | alpha-Amino-24(ethylene glycol)-omega-propionic acid |
PEG1355.0100 | H2N-dPEG(24)-COOH | C51H103NO26 | 756526-07-4 | 1146.38 | 100mg | alpha-Amino-24(ethylene glycol)-omega-propionic acid |
PEG1360.0001 | H2N-dPEG(24)-CO-OtBu | C55H111NO26 | 872340-65-3 | 1202.49 | 1g | alpha-Amino-24(ethylene glycol)-omega-propionic acid t-butyl ester |
PEG1360.0100 | H2N-dPEG(24)-CO-OtBu | C55H111NO26 | 872340-65-3 | 1202.49 | 100mg | alpha-Amino-24(ethylene glycol)-omega-propionic acid t-butyl ester |
PEG1365.0001 | H2N-EG2-CO-OtBu | C11H23NO4 | 756525-95-8 | 233.3 | 1g | 3-(2-(2-Aminoethoxy)ethoxy)propanoic acid t-butyl ester |
PEG1365.0100 | H2N-EG2-CO-OtBu | C11H23NO4 | 756525-95-8 | 233.3 | 100mg | 3-(2-(2-Aminoethoxy)ethoxy)propanoic acid t-butyl ester |
PEG1370.0001 | H2N-dPEG(4)-COOH | C11H23NO6 | 663921-15-1 | 265.3 | 1g | 15-Amino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1370.0100 | H2N-dPEG(4)-COOH | C11H23NO6 | 663921-15-1 | 265.3 | 100mg | 15-Amino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1375.0001 | H2N-dPEG(4)-CO-OtBu | C15H31NO6 | 581065-95-4 | 321.41 | 1g | 15-Amino-4,7,10,13-tetraoxa-pentadecanoic acid t-butyl ester |
PEG1375.0100 | H2N-dPEG(4)-CO-OtBu | C15H31NO6 | 581065-95-4 | 321.41 | 100mg | 15-Amino-4,7,10,13-tetraoxa-pentadecanoic acid t-butyl ester |
PEG1380.0001 | H2N-dPEG(8)-COOH | C19H39NO10 | 756526-04-2 | 441.51 | 1g | 1-Amino-3,6,9,12,15,18,21,24-octaoxaheptaeicosane-27-oic acid |
PEG1380.0100 | H2N-dPEG(8)-COOH | C19H39NO10 | 756526-04-2 | 441.51 | 100mg | 1-Amino-3,6,9,12,15,18,21,24-octaoxaheptaeicosane-27-oic acid |
PEG1385.0001 | H2N-dPEG(8)-CO-OtBu | C23H47NO10 | 756526-06-4 | 497.62 | 1g | 1-Amino-3,6,9,12,15,18,21,24-octaoxaheptaeicosane-27-oic acid t-butyl ester |
PEG1385.0100 | H2N-dPEG(8)-CO-OtBu | C23H47NO10 | 756526-06-4 | 497.62 | 100mg | 1-Amino-3,6,9,12,15,18,21,24-octaoxaheptaeicosane-27-oic acid t-butyl ester |
PEG2420.0001 | H-O2Oc-OH | C6H13NO4 | 134978-97-5 | 163.2 | 1g | [2-(2-aminoethoxy)ethoxy]acetic acid |
PEG2420.0005 | H-O2Oc-OH | C6H13NO4 | 134978-97-5 | 163.2 | 5g | [2-(2-aminoethoxy)ethoxy]acetic acid |
PEG2420.0025 | H-O2Oc-OH | C6H13NO4 | 134978-97-5 | 163.2 | 25g | [2-(2-aminoethoxy)ethoxy]acetic acid |
PEG2430.0001 | H-O2Oc-OtBu*HCI | C10H21NO4*HCI | 1122484-77-8 net | 219.28*36.45 | 1g | [2-(2-aminoethoxy)ethoxy]acetic acid tert-butyl ester*HCl |
PEG2430.0005 | H-O2Oc-OtBu*HCI | C10H21NO4*HCI | 1122484-77-8 net | 219.28*36.45 | 5g | [2-(2-aminoethoxy)ethoxy]acetic acid tert-butyl ester*HCl |
PEG2770.0001 | H-O2Oc-O2Oc-O2Oc-OH | C18H35N3O10 | - | 453.48 | 1g | 26-amino-10,19-dioxo-3,6,12,15,21,24-hexaoxa-9,18-diazahexacosan-1-oic acid |
PEG2770.0005 | H-O2Oc-O2Oc-O2Oc-OH | C18H35N3O10 | - | 453.48 | 5g | 26-amino-10,19-dioxo-3,6,12,15,21,24-hexaoxa-9,18-diazahexacosan-1-oic acid |
PEG2770.0250 | H-O2Oc-O2Oc-O2Oc-OH | C18H35N3O10 | - | 453.48 | 250mg | 26-amino-10,19-dioxo-3,6,12,15,21,24-hexaoxa-9,18-diazahexacosan-1-oic acid |
PEG3340.0100 | H2N-dPEG™(36)-COOH | C75H151NO38 | 756526-07-4 | 1674.99 | 100mg | alpha-Amino-omega-propionic acid-36(ethylen glycol) |
PEG3340.1000 | H2N-dPEG™(36)-COOH | C75H151NO38 | 756526-07-4 | 1674.99 | 1g | alpha-Amino-omega-propionic acid-36(ethylen glycol) |
PEG3690.0000 | H2N-dPEG™(16)-CO-OtBu | C39H79NO18 | 872340-65-3 | 850.04 | 0mg | alpha-Amino-omega-(t-butyl propionate) hexadeca(ethylene glycol) |
PEG3700.0000 | H2N-dPEG™(20)-CO-OtBu | C47H95NO22 | 872340-65-3 | 1026.25 | 0mg | alpha-Amino-omega-(t-butyl propionate) 20(ethylene glycol) |
PEG3710.0100 | H2N-dPEG™(36)-CO-OtBu | C79H159NO38 | 872340-65-3 | 1731.09 | 100mg | alpha-Amino-omega-(t-butyl propionate) 36(ethylene glycol) |
PEG3710.1000 | H2N-dPEG™(36)-CO-OtBu | C79H159NO38 | 872340-65-3 | 1731.09 | 1g | alpha-Amino-omega-(t-butyl propionate) 36(ethylene glycol) |
Cbz(ベンジルオキシカルボニル)保護基
ベンジルオキシカルボニル基によって保護されたアミノ-PEG-カルボン酸は、従来通りの方法で液相のペプチド合成によってPEGをスペーサーや末端官能基として組み込むことが可能です。
ベンジルオキシカルボニル保護基は、Pd/Cによる接触還元条件で脱保護されます。他の諸条件では脱保護しないため、激しい条件での実験にもお使いいただけます。
Cbz保護基を有するPEG製品
表13. Cbz保護基を有するPEG製品一覧
コード | 製品名 | 分子式 | CAS | 分子量 | 内容量 | 名称 |
---|---|---|---|---|---|---|
PEG1495.0001 | Z-NH-dPEG(4)-COOH | C19H29NO8 | 756526-00-8 | 399.44 | 1g | 15-Benzyloxycarbonylamino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1495.0100 | Z-NH-dPEG(4)-COOH | C19H29NO8 | 756526-00-8 | 399.44 | 100mg | 15-Benzyloxycarbonylamino-4,7,10,13-tetraoxa-pentadecanoic acid |
PEG1785.0001 | Z-NH-dPEG(12)-COOH | C35H61NO16 | 1334177-88-6 | 751.86 | 1g | 1-Benzyloxycarbonylamino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid |
PEG1785.0100 | Z-NH-dPEG(12)-COOH | C35H61NO16 | 1334177-88-6 | 751.86 | 100mg | 1-Benzyloxycarbonylamino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid |
PEG1790.0001 | Z-NH-dPEG(24)-COOH | C59H109NO28 | 1334177-88-6 | 1280.52 | 1g | alpha-Benzyloxycarbonylamino-24(ethylene glycol)-omega-propionic acid |
PEG1790.0100 | Z-NH-dPEG(24)-COOH | C59H109NO28 | 1334177-88-6 | 1280.52 | 100mg | alpha-Benzyloxycarbonylamino-24(ethylene glycol)-omega-propionic acid |
PEG1795.0001 | Z-NH-dPEG(6)-COOH | C23H37NO10 | 1334177-80-8 | 487.54 | 1g | 1-Benzyloxycarbonylamino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1795.0100 | Z-NH-dPEG(6)-COOH | C23H37NO10 | 1334177-80-8 | 487.54 | 100mg | 1-Benzyloxycarbonylamino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid |
PEG1800.0001 | Z-NH-dPEG(8)-COOH | C27H45NO12 | 1334177-87-5 | 575.65 | 1g | 1-Benzyloxycarbonylamino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid |
PEG1800.0100 | Z-NH-dPEG(8)-COOH | C27H45NO12 | 1334177-87-5 | 575.65 | 100mg | 1-Benzyloxycarbonylamino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid |
PEG4570.0000 | Z-NH-dPEG™(16)-COOH | C43H77NO20 | 1334177-88-6 | 928.07 | 0mg | alpha-Benzyloxycarbonylamino-hexadeca(ethylene glycol)-omega-carboxylic acid |
PEG4580.0000 | Z-NH-dPEG™(20)-COOH | C51H93NO24 | 1334177-88-6 | 1103.61 | 0mg | alpha-Benzyloxycarbonylamino-amino-20(ethylene glycol)-omega-carboxylic acid |
PEG4590.0100 | Z-NH-dPEG™(36)-COOH | C83H157NO40 | 1334177-88-6 | 1809.12 | 100mg | alpha-Benzyloxycarbonylamino-amino-36(ethylene glycol)-omega-carboxylic acid |
PEG4590.1000 | Z-NH-dPEG™(36)-COOH | C83H157NO40 | 1334177-88-6 | 1809.12 | 1g | alpha-Benzyloxycarbonylamino-amino-36(ethylene glycol)-omega-carboxylic acid |
PEG4710.0005 | Z-O1Pen-OH | C12H5NO5 | 1260092-43-0 | 253.25 | 5g | 5-(Benzyloxycarbonyl-amino)-3-oxa-pentanoic acid |
PEG4710.0025 | Z-O1Pen-OH | C12H5NO5 | 1260092-43-0 | 253.25 | 25g | 5-(Benzyloxycarbonyl-amino)-3-oxa-pentanoic acid |
ZAA1186.0001 | Z-O2Oc-OH*DCHA | C14H19NO6*C12H23N | 560088-84-8 | 297.31*181.32 | 1g | 8-(Benzyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine |
ZAA1186.0005 | Z-O2Oc-OH*DCHA | C14H19NO6*C12H23N | 560088-84-8 | 297.31*181.32 | 5g | 8-(Benzyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine |
ZAA1186.0025 | Z-O2Oc-OH*DCHA | C14H19NO6*C12H23N | 560088-84-8 | 297.31*181.32 | 25g | 8-(Benzyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine |